SCHEMBL23608965

SCHEMBL23608965

Fc1ccc(CNc2ccc(NCCn3cncn3)c(-c3ccccc3)c2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.41
NAMPT P43490 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
POLB P06746 1/20 0.36
MAPK1 P28482 2/20 0.36
QPCT Q16769 2/20 0.36
TP53 P04637 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608959 0.82 SMN1; SMN2 (0.42) CYP19A1NAMPTSMN1; SMN2LMNAMAPT
SCHEMBL23608946 0.75 SMN1; SMN2 (0.41) CYP19A1NAMPTSMN1; SMN2LMNAMAPT
SCHEMBL23608949 0.74 CYP19A1 (0.44) CYP19A1NAMPTLMNAKDM4EMAPK1
SCHEMBL23609142 0.73 CYP19A1 (0.41) CYP19A1SMN1; SMN2LMNAMAPTMEN1
SCHEMBL23608999 0.73 CYP19A1 (0.43) CYP19A1SMN1; SMN2LMNAMAPTMEN1
SCHEMBL30406544 0.72 CYP19A1 (0.40) CYP19A1NAMPTSMN1; SMN2LMNAMAPT
SCHEMBL23608979 0.72 CYP19A1 (0.42) CYP19A1NAMPTSMN1; SMN2LMNAMAPT
SCHEMBL23609006 0.72 SMN1; SMN2 (0.44) CYP19A1NAMPTSMN1; SMN2LMNAMAPT
SCHEMBL23608948 0.71 GPR55 (0.47) CYP19A1NAMPTSMN1; SMN2LMNAMEN1
SCHEMBL23608983 0.71 CYP19A1 (0.43) CYP19A1SMN1; SMN2LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 CYP19A1 153/4885NAMPT 965/4885SMN1; SMN2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.